Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)CDC Issues Guidance on COVID-19 Rebound After Paxlovid Treatment

The CDC continue to recommend Paxlovid for early-stage treatment of mild-to-moderate COVID-19 among individuals at high risk of progression to severe disease. Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms two to eight days after completing the five-day course of treatment. Both the illness and the positive test results resolved, on average, three days later without the need for additional treatment.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form